On December 15, Darui Biotech announced that its InHBE target GalNAC-conjugated siRNA drug rn3161 was recently administered in the first human phase I clinical trial to treat obesity, the first cohort. Preliminary data from this cohort showed good safety and tolerability, marking the first clinical milestone achieved by the company's INHBE program. The rest of the cohort is expected to be completed in 2026.

Zhitongcaijing · 2d ago
On December 15, Darui Biotech announced that its InHBE target GalNAC-conjugated siRNA drug rn3161 was recently administered in the first human phase I clinical trial to treat obesity, the first cohort. Preliminary data from this cohort showed good safety and tolerability, marking the first clinical milestone achieved by the company's INHBE program. The rest of the cohort is expected to be completed in 2026.